Narjust Florez
MD
Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Feb 24, 2026
Episode
350
Share
In this episode of Lung Cancer Considered, host Dr. Narjust Florez explores the evolving landscape of emerging molecular targets in NSCLC with Dr. Kelsey Pan and Rajat Thawani, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion highlights rare oncogenic drivers with a focus on clinical evidence, resistance mechanisms, and trial design. The episode also addresses biomarker testing, the role of next-generation sequencing and liquid biopsy, and what the next five years may hold for precision treatment strategies in NSCLC.
Guest
Kelsey Pan
MD, MPH
Assistant Professor of Medicine Department of Hematology & Oncology, Thoracic Medical Oncology Section
Emory University Winship Cancer Institute
Rajat Thawani
MD
Assistant Professor of Medicine Division of Hematology and Oncology
Knight Cancer Institute, OHSU
